Zai Lab inks Chi­na deal with Turn­ing Point with $25M up­front; Xen­cor, Atre­ca team up on bis­pecifics

→ Zai Lab is pay­ing out a $25 mil­lion up­front for the rights to sell Turn­ing Point Ther­a­peu­tics’ lead drug re­potrec­tinib in Greater Chi­na. The San Diego-based biotech is al­so in line for up to $151 mil­lion in mile­stones, along with mid-to-high teen roy­al­ties. Zai plans to add sites to the Phase II tri­al of the drug, which is de­signed to treat ROS1-pos­i­tive ad­vanced NSCLC in pa­tients who were not pre­vi­ous­ly treat­ed with a TKI.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER